Medical Mythbusting Commentary for March 27, 2023
[display_podcast]
Source:
Prostate cancer: New combination therapy could reduce progression risk
Reference:
TALAPRO-2 Supports First-Line Talazoparib/Enzalutamide in All-Comers With mCRPC
Medical Mythbusting Commentary for March 27, 2023
[display_podcast]
Source:
Prostate cancer: New combination therapy could reduce progression risk
Reference:
TALAPRO-2 Supports First-Line Talazoparib/Enzalutamide in All-Comers With mCRPC